Usefulness of FDG-PET/CT to predict the response after pembrolizumab in patients with PD-L1 positive advanced non-small cell lung cancer

Usefulness of FDG-PET/CT to predict the response after pembrolizumab in patients with PD-L1 positive advanced non-small cell lung cancer - FDG-PET/CT and prediction of pembrolizumab in lung cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026730

Enrollment

Registered

2017-03-30

Start date

2017-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced non-small cell lung cancer

Interventions

All patients undergo FDG-PET/CT before and 4 weeks after initiation of pembrolizumab therapy.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Pathologically confirmed advanced non-small cell lung cancer (NSCLC), and PD-L1 positive advanced NSCLC 2) Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 3) Patient with evaluable lesion based on RECIST 4) Written informed consent

Exclusion criteria

Exclusion criteria: 1) Pregnant woman 2) Patients with obvious interstitial pneumonia or pulmonary fibrosis in the chest X-ray. 3) Patients with collagen vascular disease or autoimmune diseases 4) Other cases attending physician it is determined unsuitable for registration of the study

Design outcomes

Primary

Measure	Time frame
Changeing of SUVmax, MTV and TLG, and the efficacy of pembrolizumab Evaluation after 1 month from administration of pembrolizumab	—

Secondary

Measure	Time frame
Survival and adverse events	—

Countries

Japan

Contacts

Public ContactKyochi Kaira

Gunma University Oncology Clinical Development

kkaira1970@yahoo.co.jp027-220-8222

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026